TB Research

A case of severe thrombocytopenia after the first exposure to rifampicin

Nakane C, Nishimoto K, Kishimoto E, Suzuki K, Nakagawa E, Morikawa M, Murakami Y, Aoshima Y, et al. (12 authors)

Respiratory medicine case reports · 2023-02

Abstract

Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 10 3 /μL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.